2026-03-09T14:36:23Z https://mie-u.repo.nii.ac.jp/oai

oai:mie-u.repo.nii.ac.jp:00008102 2023-10-12T03:01:02Z 631:632:633

原発性肝がんに対するシスプラチン・リピオドール療法時の有害事象調査 宮澤, 憲治 Miyazawa, Kenji 世古口, 典子 Sekoguchi, Noriko 岩本, 卓也 Iwamoto, Takuya 村木, 優一 Muraki, Yuichi 田中, 秀明 Tanaka, Hideaki 岩佐, 元雄 Iwasa, Motoh 山門, 享一郎 Yamakado, Kouichiro 竹田, 寛 Takeda, Kan 竹井, 謙之 Takei, Yoshiyuki 奥田, 真弘 Okuda, Masahiro cisplatin lipiodol hepatocellular carcinoma adverse events thrombocytopenia application/pdf Transcatheter arterial embolization (TAB) and transcatheter arterial infusion (TAI) using cisplatin suspended in Lipiodol® Ultra-Fluide (Cisplatin/Lipiodol) are considered to be useful tumor-targeting therapies for hepatocellular carcinoma. However, little information is available on adverse events due to injection of Cisplatin/Lipiodol because the combined use Lipiodol and Cisplatin has not been approved by the Japanese government yet. Upon investigating the frequency and time of onset of adverse events following injection of Cisplatin/Lipiodol in 16 in-patients at Mie University Hospital, the frequency of the subjective symptoms of stomachache including epigastrium ache (75.0%), nausea or vomiting (50.0%), fever (50.0%), and gastric region discomfort (37.5%) was observed to be high. Further, leucocytes and neutrophils increased 2 days after injection (p< 0.001) and the onset of thrombocytopenia was much earlier than that following injection of Cisplatin alone. Severe adverse events defined as grade 3 or 4 in the Common Toxicity Criteria for Adverse Events Version 3.0 (JCOG/JSCO version, National Cancer Institute) were observed in 12 patients. These results suggest that great caution should be exercised with respect to adverse events occurring during Cisplatin/Lipiodol therapy. 日本医療薬学会 2008-08-10 jpn journal article VoR http://hdl.handle.net/10076/12238 https://mie-u.repo.nii.ac.jp/records/8102 AA11527197 1346-342X 医療薬学 34 8 794 799 https://mie-u.repo.nii.ac.jp/record/8102/files/39A16148.pdf application/pdf 88.2 kB 2017-02-18